Current Treatment Practices in Embolization-Eligible HCC
Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), particularly for patients with progressive or extensive disease. In locally advanced cases, systemic therapies, including immunotherapy combinations and tyrosine kinase inhibitors (TKIs), are first-line options. Patients typically transition from transarterial chemoembolization (TACE) to systemic therapy upon progression, high tumor burden, or liver function decline.
Video content above is prompted by the following:
- Discuss the current role of systemic therapy in the embolization-eligible setting of HCC.
- How are systemic therapies currently used in patients with locally advanced disease?
- Is there a role for TKIs in first-line treatment?
- In current clinical practice, when do patients typically transition from embolization-based therapies like TACE to systemic ones?
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
